Pharaoh Neuro Receives FDA Breakthrough Designation for Novel CSF Filtration System
Pharaoh Neuro has received FDA Breakthrough Device Designation for its Neurapheresis™ Cerebrospinal Fluid (CSF) Management System, developed to accelerate the removal of blood and blood-breakdown products from cerebrospinal fluid following aneurysmal subarachnoid haemorrhage (aSAH). The designation supports closer interaction with the FDA during the device's development and regulatory review.
Aneurysmal subarachnoid haemorrhage is a type of haemorrhagic stroke in which blood enters the space surrounding the brain. Blood and its breakdown products can affect the cerebrospinal fluid environment and contribute to secondary brain injury.
The Neurapheresis system uses a closed-loop, external and automated platform to circulate a patient's own CSF through a filtration process. It is designed to remove blood and blood-breakdown products before returning the filtered fluid to the patient, without introducing replacement fluids.
Unlike conventional passive CSF drainage systems, the technology actively filters cerebrospinal fluid to accelerate the clearance of blood-related substances.
Its safety and feasibility were evaluated in the PILLAR-XT clinical study, published in Neurocritical Care. The study reported that active filtration accelerated the removal of blood and its breakdown products from CSF following aneurysmal subarachnoid haemorrhage.
The system remains investigational and has not received FDA marketing approval or clearance. Its development aims to provide an additional approach to CSF management and address an unmet need in neurocritical care.